Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1

Arthur F. Kavanaugh, Laurie S. Davis, Lisa A. Nichols, Stephen H. Norris, Robert Rothlein, Linda A. Scharschmidt, Peter E. Lipsky

Research output: Contribution to journalArticle

255 Scopus citations

Abstract

Objective. To assess the safety and efficacy of a monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM‐1; CD54) in rheumatoid arthritis (RA). Methods. A phase I/II, open‐label, dose‐escalation study of 32 patients. Results. During treatment, a peripheral CD3+/CD4+ lymphocytosis was noted, and several patients demonstrated transient cutaneous anergy, which suggests that therapy modified T cell recirculation. Thirteen of the 23 patients who received 5 days of treatment demonstrated clinical improvement through day 29, and 9 of 23 through day 60. Adverse effects were minor and transient. Conclusion. Anti—ICAM‐1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.

Original languageEnglish (US)
Pages (from-to)992-999
Number of pages8
JournalArthritis & Rheumatism
Volume37
Issue number7
DOIs
StatePublished - Jul 1994

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1'. Together they form a unique fingerprint.

  • Cite this

    Kavanaugh, A. F., Davis, L. S., Nichols, L. A., Norris, S. H., Rothlein, R., Scharschmidt, L. A., & Lipsky, P. E. (1994). Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis & Rheumatism, 37(7), 992-999. https://doi.org/10.1002/art.1780370703